Ubs Oconnor LLC Zentalis Pharmaceuticals, Inc. Transaction History

Ubs Oconnor LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $1.33 Million - $2.08 Million	-65,600 Reduced 82.9%	13,527 $293 Million
Q2 2022 Aug 12, 2022	BUY	$17.91 - $52.25 $1.1 Million - $3.22 Million	61,625 Added 352.1%	79,127 $2.22 Million
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $727,733 - $1.42 Million	17,502 New	17,502 $807,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.